Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb - Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb - Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
📈 **POSITIVE** • Low confidence analysis (38%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (75%) **Content type:** General